AtriCure stock rises 20 percent on approval news

June 16, 2010 by MedCity News

The Food & Drug Administration's approval of AtriCure Inc.'s AtriClip system could be a boon not only for heart patients, but investors, too.

MedCity News logo

By Mary Vanac

Shares of West Chester, Ohio-based AtriCure Inc. (NASDAQ:ATRC) rose more than 20 percent Tuesday, a day after the Food & Drug Administration approved the company's AtriClip system for sale in the United States.

AtriCure shares rose as high as $7.20, ending the day up $1.07 at $6.30. More than 1 million AtriCure shares traded hands. That's 26 times as many shares than traded on any day in the last three months.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.